Lymphoma Clinical Trials in Pittsburgh

Showing 281-300 of 675 trials

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

NCT04745234

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

Cutaneous T-Cell Lymphoma, RelapsedCutaneous T-Cell Lymphoma Refractory

Kyowa Kirin, Inc.34 participantsStarted Aug 2021

Duarte, California, United States • Irvine, California, United States • Stanford, California, United States +13 more locations

UNKNOWNPhase 1/2< 1 mile

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

NCT05358379

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.

Solid Tumor, Adult Lymphoma

Cyclacel Pharmaceuticals, Inc.330 participantsStarted Apr 2022

Duarte, California, United States • Pittsburgh, Pennsylvania, United States • Houston, Texas, United States +2 more locations

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Lymphoma Trials in Other Cities

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Other Conditions in Pittsburgh